Ultrasound-Based TestingFibrosis Assessment
Imaging-Based Diagnostic Tests • Diagnostic Tests With Ultrasound

Interpretation of Ultrasound-Based Elastography Clinical Cutoffs

Rule-of-5s kPa interpretation for VCTE and standardized vendor-agnostic kPa and m/s thresholds for ARFI shear wave elastography.

What This Means for Patients

Clinicians often use a 'Rule of 5s' to translate your kPa stiffness number into plain English. On a FibroScan (VCTE), a score of 5 kPa or lower is typically normal, anything under 10 kPa makes advanced chronic liver disease very unlikely, 10 to 15 kPa enters a watch-closely zone, 15 kPa or higher confirms advanced scarring, and 20 to 25+ kPa alerts your liver specialist to check for elevated vein pressure (portal hypertension), especially when paired with your platelet count.

Interpretation of LSM by VCTE™ (Baveno VII “Rule of 5s”)1,4

VCTE™-LSM, kPa Interpretation
≤5 High probability of being normal
<10 Exclude cACLD: risk of LREs is negligible
≥10 to <15 Potential cACLD: risk of LREs starts to increase
In the presence of platelets ≥150 × 109/L: exclude CSPH
≥15 to <20 Confirm cACLD: clinically relevant risk of LREs
In the presence of platelets ≥150 × 109/L: exclude HRVs (<5% risk; endoscopy spared)4
≥20 to <25 cACLD with potential CSPH (“gray zone” for CSPH)a
≥25 Assume CSPH in non-obese MASH (BMI <30 kg/m2); in obese MASH (BMI ≥30 kg/m2), apply ANTICIPATE-NASHb

Interpretation of LSM Obtained Using ARFI-SWE1,2

ARFI-SWE, kPa ARFI-SWE, m/s Interpretation
≤5 1.3 High probability of being normal1,2
<9 1.7 In the absence of other known clinical signs, rules out cACLD. If signs are present, further testing may be needed1,2
9–13 1.7–2.1 Suggestive of cACLD; further testing is required for confirmation1,2
>13 2.1 Rules in cACLD1,2
>17 2.4 Suggestive of CSPH1,2
>21 2.6 High probability of CSPH1

Portal Hypertension Refinement: Obese MASH (ANTICIPATE-NASH) & Spleen Stiffness (SSM)4-6

Tool / Consensus Rule Key Thresholds Clinical Action (Baveno VII & AASLD 2025 NILDA)
ANTICIPATE-NASH Model4,6
Obese MASH (BMI ≥30 kg/m2)
Combines BMI + VCTE LSM + Platelets Because VCTE ≥25 kPa alone overestimates CSPH in patients with BMI ≥30 kg/m2, use the ANTICIPATE-NASH nomogram to estimate true CSPH probability before initiating carvedilol / NSBB therapy4,6
Spleen Stiffness Measurement (SSM)4,5 ≤21 kPa: Rule out CSPH
≥50 kPa: Rule in CSPH
Resolves the VCTE 15–25 kPa / obese MASH CSPH gray zone at the same bedside session and further reduces unnecessary screening endoscopies4,5
Recent efforts to standardize across the industry have led to unified SWE thresholds (from 2019+) that are vendor agnostic.1-3